- •Diabetic Retinopathy
- •Preface
- •Contents
- •Contributors
- •Nonproliferative Diabetic Retinopathy
- •Nonproliferative Diabetic Retinopathy
- •Inflammatory Mechanisms
- •Microaneurysms
- •Vascular Permeability
- •Capillary Closure
- •Classification Of Nonproliferative Retinopathy
- •Macular Edema
- •Risk Factors For Progression Of Retinopathy
- •Severity of Retinopathy
- •Glycemic Control
- •The Diabetes Control and Complications Trial
- •Epidemiology of Diabetes Interventions and Complications Trial
- •The United Kingdom Prospective Diabetes Study
- •Hypertension
- •The United Kingdom Prospective Diabetes Study
- •Appropriate Blood Pressure Control in Diabetes Trials
- •Elevated Serum Lipid Levels
- •Pregnancy and Diabetic Retinopathy
- •Other Systemic Risk Factors
- •Management Of Nonproliferative Diabetic Retinopathy
- •Photocoagulation
- •Scatter Photocoagulation for Nonproliferative Diabetic Retinopathy
- •Scatter Photocoagulation for Proliferative Retinopathy
- •Focal Photocoagulation for Diabetic Macular Edema
- •Other Treatment of Diabetic Macular Edema
- •Medical Therapy
- •Aspirin And Antiplatelet Treatments
- •Aldose Reductase Inhibitors
- •Other Medical Treatments
- •Summary
- •Acknowledgment
- •References
- •Proliferative Diabetic Retinopathy
- •Development and Natural History
- •Histopathology and Early Development
- •Proliferation and Regression of New Vessels
- •Contraction of the Vitreous and Fibrovascular Proliferations
- •Retinal Distortion and Detachment
- •Burned-Out Proliferative Diabetic Retinopathy
- •Systemic Associations
- •Proliferative Diabetic Retinopathy and Glycemic Control
- •Other Risk Factors for Proliferative Diabetic Retinopathy
- •Rubeosis Iridis
- •Anterior Hyaloidal Fibrovascular Proliferation
- •Management of Proliferative Diabetic Retinopathy
- •Pituitary Ablation
- •Photocoagulation
- •Randomized Clinical Trials of Laser Photocoagulation
- •The Diabetic Retinopathy Study
- •Risks and Benefits Photocoagulation In The Drs
- •The Early Treatment Diabetic Retinopathy Study
- •Indications For Photocoagulation of Pdr
- •PRP and Macular Edema
- •PRP Treatment Techniques
- •Vitrectomy for PDR
- •Pharmacologic Treatment of PDR
- •Acknowledgment
- •References
- •Brief Historical Background
- •The Wesdr
- •Prevalence of Diabetic Retinopathy
- •Incidence of Diabetic Retinopathy
- •Diabetic Retinopathy in African American and Hispanic Whites
- •Native Americans and Asian Americans
- •Age and Puberty
- •Genetic and Familial Factors
- •Modifiable Risk Factors
- •Hyperglycemia
- •Clinical Trials of Intensive Treatment of Glycemia
- •Diabetes Control and Complications Trial
- •The United Kingdom Diabetes Prospective Study (UKPDS)
- •Hypertension
- •Lipids
- •Subclinical and Clinical Diabetic Nephropathy
- •Microalbuminuria and Diabetic Retinopathy
- •Gross Proteinuria and Retinopathy
- •Diabetic Retinopathy as a Risk Indicator of Subclinical Nephropathy
- •Other Risk Factors For Retinopathy
- •Smoking and Drinking
- •Body Mass Index and Physical Activity
- •Hormone and Reproductive Exposures in Women
- •Prevalence and Incidence of Visual Impairment
- •Conclusions
- •Acknowledgments
- •References
- •Introduction
- •Fluorescein Angiography
- •Properties
- •Side Effects
- •Normal Fluorescein Angiography
- •Terminology
- •Fluorescein Angiography in the Evaluation of Diabetic Retinopathy
- •Fluorescein Angiography in the Evaluation of Diabetic Macular Edema
- •Optical Coherence Tomography
- •Low-Coherence Interferometry
- •OCT Image Interpretation
- •OCT Technology Development
- •The Role of OCT in Diabetic Macular Edema
- •Morphologic Patterns of Diabetic Macular Edema
- •Clinical Applications of OCT in Diabetic Macular Edema
- •Conclusions
- •References
- •Diabetic primates
- •Type of Diabetes
- •Histopathology and Rate of Development of the Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic dogs
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic cats
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic rats
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neuronal disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic mice
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neural disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Other Rodents
- •Galactose Feeding
- •Nondiabetic Models in Which Growth Factors are Altered
- •VEGF overexpression
- •IGF overexpression
- •PDGF-B-deficient mice
- •Oxygen-Induced Retinopathy
- •Sympathectomy
- •Retinal Ischemia–Reperfusion
- •Summary
- •References
- •Introduction
- •Biochemistry and Genetics of The Polyol Pathway
- •Aldose Reductase
- •The Aldose Reductase Enzyme
- •The Aldose Reductase Gene
- •Polymorphisms of the AR Gene
- •Sorbitol Dehydrogenase
- •The Sorbitol Dehydrogenase Enzyme
- •The Sorbitol Dehydrogenase Gene
- •Ar Polymorphisms and Risk of Diabetic Retinopathy
- •Sdh Polymorphisms and Diabetic Retinopathy
- •Ar Overexpression
- •Sdh Overexpression
- •Ar “Knockout” Mice
- •Sdh-Deficient Mice
- •Osmotic Stress
- •Oxidative Stress
- •Activation of Protein Kinase C
- •Generation of AGE Precursors
- •Proinflammatory Events and Apoptosis
- •Ari Structures and Properties
- •Effects of Aris in Experimental Diabetic Retinopathy
- •The Polyol Pathway in Human Diabetic Retinopathy
- •The Sorbinil Trial
- •Perspective and Needs
- •Rationale for Defining the Pathogenic Role of the Polyol Pathway
- •Needs to be Met to Arrive at Anti-Polyol Pathway Therapy
- •References
- •Introduction to Diabetic Retinopathy
- •Biochemistry of Age Formation
- •Pathogenic Role of Ages In Diabetic Retinopathy
- •AGEs and Clinical Correlation of Diabetic Retinopathy
- •AGE Accumulation in the Eye
- •Effect of AGEs on Retinal Cells
- •RAGE in Diabetic Retinopathy
- •Other AGE Receptors in Diabetic Retinopathy
- •Anti-Age Strategies For Diabetic Retinopathy
- •Conclusion
- •References
- •Introduction
- •Dag-Pkc Pathway
- •Diabetes and Retinal Blood Flow
- •Basement Membrane and Ecm Changes
- •Vascular Permeability and Angiogenesis
- •Conclusions
- •References
- •Sources of Oxidative Stress in The Diabetic Retina
- •Overview
- •Mitochondrial Electron Transport Chain (ETC)
- •Advanced Glycation End (AGE) Product Formation
- •Cyclo-oxygenase (COX)
- •Flux Through Aldose Reductase (AR) Pathway
- •Activation of Protein Kinase C (PKC)
- •Endothelial NO Synthase (eNOS)
- •Inducible NOS (iNOS)
- •NADPH Oxidase
- •Antioxidants in Diabetic Retinopathy
- •Overview
- •Glutathione (GSH)
- •Superoxide Dismutase (SOD)
- •Catalase
- •Effects of Oxidative Stress in The Diabetic Retina
- •Overview
- •Growth Factors and Cytokines
- •Cytoxicity
- •Therapeutic Strategies For Reducing Oxidative Stress
- •Overview
- •Antioxidants
- •PKC Inhibitors
- •Inhibitors of the Renin-Angiotensin System
- •Inhibitors of the Polyol Pathway
- •HMG-CoA Reductase Inhibitors (Statins)
- •PEDF
- •Cannabinoids
- •Cyclo-oxygenase-2 (COX-2) Inhibitors
- •References
- •Pericyte Loss in the Diabetic Retina
- •Introduction
- •Origin and Differentiation
- •Morphology and Distribution
- •Identification
- •Function
- •Contractility
- •Role in Vessel Formation and Stabilization
- •Loss In Diabetic Retinopathy
- •Rats
- •Mice
- •Chinese Hamster
- •Animal Models Mimicking Retinal Pericyte Loss
- •Pdgf-B-Pdgf-Ssr
- •Angiopoietin-Tie
- •Vegf-Vegfr2
- •Mechanisms of Loss
- •Biochemical Pathways
- •Aldose Reductase
- •Age Formation
- •Modification of Ldl
- •Loss Through Active Elimination
- •Capillary Dropout in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Methods to Measure and Detect Capillary Dropout
- •Models to Study Retinal Capillary Dropout in Diabetes
- •Potential Mechanisms For Capillary Dropout
- •Capillary Cell Apoptosis
- •Proinflammatory Changes/Leukostasis
- •Microthrombosis/Platelet Aggregation
- •Consequences of Capillary Dropout
- •Macular Ischemia
- •Neovascularization
- •Macular Edema
- •Acknowledgments
- •References
- •Neuroglial Dysfunction in Diabetic Retinopathy
- •The Neurons of The Retina
- •The Glial Cells of The Retina
- •Diabetes Reduces Retinal Function
- •Diabetes Induces Neurodegeneration in The Retina
- •Neuroinflammation in Diabetic Retinopathy
- •Historical Perspective on Diabetic Retinopathy
- •Neuroglial Dysfunction in Diabetic Retinopathy.
- •References
- •Introduction
- •Inflammatory Cells Promote and Regulate The Development of Ischemic Ocular Neovascularization
- •VEGF as a Proinflammatory Factor in Diabetic Retinopathy
- •VEGF164/165 as a Proinflammatory Cytokine
- •Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- •Corticosteroids
- •Anti-VEGF Agents
- •Pegaptanib
- •Ranibizumab and Bevacizumab
- •Conclusions
- •Acknowledgment
- •References
- •Glia-Endothelial Interaction
- •Specialized Retinal Vessels Control Flux into Neural Tissue
- •Overview of Tight Junction Proteins
- •Claudins Confer Tight Junction Barrier Properties
- •Occludin Regulates Barrier Properties
- •Alterations in Occludin in Diabetic Retinopathy
- •Ve-Cadherin and Diabetic Retinopathy
- •Permeability in Diabetic Retinopathy
- •Summary and Conclusions
- •References
- •Introduction
- •Stages of Angiogenesis
- •Vascular Endothelial Growth Factor
- •Regulation of Vegf Expression in The Retina
- •Regulation of VEGF in Proliferative Diabetic Retinopathy
- •Regulation of VEGF in Nonproliferative Diabetic Retinopathy
- •Basic Vegf Biology
- •Receptors
- •Vegf’S Multiple Actions on Retinal Endothelial Cells
- •Main Signaling Pathways
- •Other Actions of Vegf
- •Proinflammatory Effects of VEGF
- •VEGF and Retinal Neuronal Development
- •VEGF and Neuroprotection
- •Modulation of Vegf Action By Other Growth Factors
- •Conclusion
- •References
- •Insulin-Like Growth Factor
- •Basic Fibroblast Growth Factor
- •Angiopoietin
- •Erythropoietin
- •Hepatocyte Growth Factor
- •Tumor Necrosis Factor
- •Extracellular Proteinases
- •The Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Proteinases in Retinal Neovascularization
- •Integrins
- •Endogenous Inhibitors of Neovascularization
- •Pigment Epithelium Derived Growth Factor
- •Angiostatin and Endostatin
- •Thrombospondin-1
- •Tissue Inhibitor of Matrix Metalloproteinases
- •Clinical Implications
- •Acknowledgments
- •References
- •Introduction
- •Pathogenesis
- •Vascular Endothelial Growth Factor (Vegf)
- •Vegf in Physiological and Pathological Angiogenesis
- •Vegf in Ocular Neovascularization
- •Vegf and Diabetic Retinopathy
- •Clinical Application of Anti-VEGF Drugs
- •Pegaptanib
- •Bevacizumab
- •Ranibizumab
- •Use of Anti-VEGF Therapies in Diabetic Retinopathy
- •Safety
- •Clinical Experience with Bevacizumab in Diabetic Retinopathy
- •Ranibizumab in Diabetic Macular Edema
- •Effect on Foveal Thickness and Macular Volume
- •Effect on Visual Acuity
- •Summary
- •References
- •Introduction
- •Pkc Inhibition With Ruboxistaurin
- •Early Clinical Trials With Rbx
- •Rbx and Progression of Diabetic Retinopathy
- •Ongoing Trials With Rbx
- •Rbx and Other, Nonocular Complications of Diabetes
- •Safety Profile of Rbx
- •Clinical Status of Rbx
- •Conclusions
- •References
- •The Role of Intravitreal Steroids in the Management of Diabetic Retinopathy
- •Clinical Efficacy
- •Safety
- •Pharmacology
- •Pharmacokinetics
- •Combination With Laser Treatment
- •Clinical Guidelines
- •Macular Edema Caused by Focal Parafoveal Leak
- •Widespread Heavy Diffuse Leak
- •Macular Edema and High-Risk Proliferative Retinopathy
- •Macular Edema Prior to Cataract Surgery
- •Juxtafoveal Hard Exudate With Heavy Leak
- •Control of Systemic Risk Factors
- •The Future of Intravitreal Steroid Therapy
- •References
- •Overview
- •Introduction and Historical Perspective
- •Growth Hormone and Diabetic Retinopathy
- •The IGF-1 System and Retinopathy
- •The Role of SST in Diabetic Retinopathy
- •Rationale for the Clinical use of Octreotide
- •Clinical evidence for sst as a therapeutic for pdr
- •Potential Reasons for Mixed Success in Clinical Trials
- •Future Direction: Sst Analogs in Combination Therapy
- •Conclusion
- •Acknowledgements
- •Introduction
- •Diabetic Retinopathy and Mortality
- •Diabetic Retinopathy and Cerebrovascular Disease
- •Diabetic Retinopathy and Heart Disease
- •Diabetic Retinopathy, Nephropathy, and Neuropathy
- •Conclusion
- •References
- •Name Index
338 |
Antonetti et al. |
MOLECULAR COMPOSITION OF THE BLOOD–RETINAL BARRIER
Specialized Retinal Vessels Control Flux into Neural Tissue
The blood vessels of the CNS, including the retina, are different from blood vessels in other regions of the body. Vessels of the CNS lack fenestrations observed in highly permeable vessels such as the glomerular capillary wall (22) and choroid capillary plexus (23). These fenestrations are a thinning of the capillary wall, bringing the apical and basal membranes in close apposition and promoting transcellular flux. This loss of endothelial cell fenestrations is one of the initial developmental steps of BBB formation (24, 25). Additionally, the vessels of the CNS have reduced pinocytotic vesicles, also reducing transcellular transport (26–28). These structural features allow specific control of transcellular permeability through specific mechanisms such as receptor-mediated endocytosis, and provide tight control of the fluids, nutrients, and metabolic precursors that enter the neural parenchyma.
Overview of Tight Junction Proteins
Paracellular flux is controlled by the presence and composition of the junctional complex, which includes both tight junctions and adherens junctions. In epithelial cells the adherens and tight junctions are easily discernable, but in the endothelium of the BBB and BRB these complexes cannot be differentiated at the ultrastructural level (29, 30). Many studies of the tight junction have been carried out in epithelial cells and a number of reviews have detailed the molecular components of the tight junctions including (31–34), and recently addressed by our group (1). Here the overall structure of the tight junction is briefly reviewed and the changes that occur to the tight junction in diabetes are addressed.
Tight junctions are now known to be complex structures comprised of over 40 structural and regulatory proteins. Figure 2 provides a schematic of the vascular structure in the retina and a highly simplified view of the tight junction complex. (For a more detailed review of the tight junction proteins in the retina see the following review and text (1, 35) ). Current concepts of the tight junctions suggest an organization of this complex array of proteins. Tight junctions are composed of both transmembrane proteins that create the connection to the adjoining cell, and organizing proteins that bind to multiple junctional proteins and link these proteins to the cytoskeleton.
The tight junction transmembrane proteins include junction adhesion molecules or JAM, occludin, tricellulin, and the claudin gene family. The most well-studied mem- brane-associated proteins that organize the junctional complex are the zonula occludens isoforms or ZO-1, -2, and -3 proteins. Recent studies using siRNA for the ZO isoforms reveals that this protein is necessary for proper assembly of the junctional complex (36), confirming a role for these proteins as a scaffold. Other studies are beginning to elucidate the molecular function of the transmembrane proteins of the tight junction.
Claudins Confer Tight Junction Barrier Properties
Cell-culture experiments utilizing siRNA (37) or mutational analysis (38) and in vivo analysis of transgenic mice have demonstrated that claudins confer barrier properties to the tight junctions (39–44). Claudins are a multigene family comprised of at least 24
Vascular Permeability in Diabetic Retinopathy |
339 |
G
P
E
ZO-1 |
ZO-1 |
Fig. 2. Blood–retinal barrier is induced by glia and pericytes. Blood vessels are comprised of endothelial cells (E) and pericytes (P) that are contacted by glial processes (G). Together, the glia and pericytes induce the tight junction complex (inset). This highly simplified version of the tight junction emphasizes the transmembrane proteins occludin (longer cytoplasmic carboxy-tail) and claudins that create the barrier. The zonula occludens protein (ZO) connects these transmembrane proteins to the cytoskeleton. Tight junctions are now known to have over 40 proteins, and the contribution of these proteins to retinal endothelial barrier properties and the changes in these proteins that occur in diabetes are just beginning to be addressed. However, occludin phosphorylation state, cellular distribution, and content are all altered in diabetes.
isoforms (45). The claudins are tetraspan transmembrane proteins with two extracellular loops and a short carboxy intracellular tail that interacts with the PDZ-1 domains of ZO-1, -2, and -3 (46). The barrier property of a given tissue depends on the expression pattern of claudins. Claudins interact in both, a homologous and heterologous fashion,
340 |
Antonetti et al. |
creating the barrier and simultaneously forming ion specific pores within the barrier (47). Thus, charge-selective paracellular pores across the tight junction may be formed.
The expression pattern of claudins in the retina has only been partially characterized. The expression of Claudin 5 is largely restricted to the vasculature (41) and has been identified in retinal (48) and brain microvessels (49). Gene deletion of Claudin 5 results in permeability to molecules less than 800 Da and neonatal lethality (50). In chick retinal pigment epithelium, expression of Claudins 1, 2, and 5 was demonstrated by embryonic Day 14 at both the protein and mRNA level (51). A comprehensive study of the expression pattern of claudins in the retina and changes in claudin expression in diabetic retinopathy is needed.
Occludin Regulates Barrier Properties
While claudins confer barrier properties to the tight junctions, occludin appears to regulate the cells response to the external signals that control barrier properties. Occludin content correlates well with barrier properties, and is higher in cells with a tighter barrier, such as the retinal endothelial cells of arterioles and capillaries, and lower in cells known to be more permeable, such as venous endothelial cells and endothelial cells of nonneuronal tissues (48, 52, 53). Since occludin was the first transmembrane tight junction protein identified, and a number of expression studies suggested occludin contributed to barrier properties (54, 55) it was thought that this protein was a structural protein in tight junctions.
Studies of occludin knock-out mice changed the view of occludin. Occludin knock-out mice are viable and tight junctions appear normal, as assessed by electron microscopy. Studies of visceral endoderm cells originating from embryonic stem cells lacking occludin support the observations in knockout mice, that occludin is not required to maintain TJ structure (56). However, the occluding-deficient mice do possess a diverse number of abnormalities, including postnatal growth retardation, male infertility, and inability of females to suckle their young, suggesting that this protein has an important regulatory function in several tissues that possess tight junctions. Additionally, salivary gland abnormalities, thinning of compact bone, brain calcium deposits, and hyperplasia of the gastric epithelium are other consequences of occludin gene deletion in mice (57,58). The role of occludin in regulation of epithelial cell division was further supported by the ability of exogenous occludin expression to revert the phenotype of raf transformed cells (59). In studies conducted in our laboratory, antisense RNA to occludin induced the RPE cell line ARPE19 to increase cell division by approximately twofold (manuscript submitted). Therefore, occludin contributes to control of cell division in cells that express tight junctions. Understanding this process is just beginning and a role for occludin in controlling angiogenesis of the blood vessels of the CNS has not been investigated.
Recent studies using small inhibitory (siRNA) to reduce occludin expression reveal a regulatory role for this protein in the cell’s response to changes in the environment as well as a direct contribution to barrier properties. A stable epithelial cell line with occludin gene expression almost completely reduced through siRNA, demonstrated increased permeability to small organic cations, such as ethanolamine and arginine (60). But even more intriguing was the lack of normal response to cholesterol depletion. Cholesterol depletion dramatically reduced the electrical resistance of the cell monolayer
